Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124518
Filing Date
2024-11-12
Accepted
2024-11-12 06:42:31
Documents
55
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nuvl-20240930.htm   iXBRL 10-Q 2337777
2 EX-10.1 nuvl-ex10_1.htm EX-10.1 27901
3 EX-10.2 nuvl-ex10_2.htm EX-10.2 174584
4 EX-31.1 nuvl-ex31_1.htm EX-31.1 16667
5 EX-31.2 nuvl-ex31_2.htm EX-31.2 16676
6 EX-32.1 nuvl-ex32_1.htm EX-32.1 9707
7 EX-32.2 nuvl-ex32_2.htm EX-32.2 8477
8 GRAPHIC img240559158_0.jpg GRAPHIC 173738
  Complete submission text file 0000950170-24-124518.txt   7109633

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20240930.xsd EX-101.SCH 763450
58 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20240930_htm.xml XML 874325
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40671 | Film No.: 241443104
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)